Gene therapy for prostate cancer

Current Oncology Reports

Volumn 3, Issue 5, 2001, Pages 438-447

  Gingrich, Jeffrey R ^a   Chauhan, Ravi D ^a   Steiner, Mitchell S ^a  

^a UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

Author keywords

Cytosine Deaminase; Gene Therapy; Herpes Simplex Virus Thymidine Kinase; Prostate Cancer; Radical Prostatectomy

Indexed keywords

CLINICAL TRIAL; GENE THERAPY; HUMAN; IMMUNOTHERAPY; MALE; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PROSTATE TUMOR; REVIEW;

CLINICAL TRIALS; COMBINED MODALITY THERAPY; GENE THERAPY; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS;

EID: 0035464818     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-001-0031-6     Document Type: Article

References (58)

1. Vile RG, Russell SJ, Lemoine NR: Cancer gene therapy: hard lessons and new courses. Gene Ther 2000, 7:2–8. This is an excellent and concise review of the field of gene therapy. DOI: 10.1038/sj.gt.3301084
2. Monahan PE, Samulski RJ: AAV vectors: is clinical success on the horizon? Gene Ther 2000, 7:24–30. This is an excellent review of recent progress in adeno-associated virus vectors that may be the preferred viral vector of the future. DOI: 10.1038/sj.gt.3301109
3. Li S, Huang L: Nonviral gene therapy: promises and challenges. Gene Ther 2000, 7:31–34. This is an outstanding review of nonviral gene therapy vectors. DOI: 10.1038/sj.gt.3301110
4. Marshall E: FDA halts all gene therapy trials at Penn [news]. Science 2000, 287:565,567.
5. Hall SJ, Bar-Chama N, Ta S, et al.: Direct exposure of mouse spermatogenic cells to high doses of adenovirus gene therapy vector does not result in germ cell transduction. Hum Gene Ther 2000, 11:1705–1712. DOI: 10.1089/10430340050111359
6. Paielli DL, Wing MS, Rogulski KR, et al.: Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse. Mol Ther 2000, 1:263–274. DOI: 10.1006/mthe.2000.0037
7. Yeung F, Li X, Ellett J, et al.: Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells. J Biol Chem 2000, 275:40846–40855. DOI: 10.1074/jbc.M002755200
8. Siemens DR, Austin JC, Hedican SP, et al.: Viral vector delivery in solid-state vehicles: gene expression in a murine prostate cancer model. J Natl Cancer Inst 2000, 92:403–412. DOI: 10.1093/jnci/92.5.403
9. Berges RR, Furuya Y, Remington L, et al.: Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc Natl Acad Sci U S A 1993, 90:8910–8914. DOI: 10.1073/pnas.90.19.8910
10. Steiner MS, Gingrich JR: Gene therapy for prostate cancer: where are we now? J Urol 2000, 164:1121–1136. This is a comprehensive review of preclinical data and clinical gene therapy trials for prostate cancer. DOI: 10.1016/S0022-5347(05)67127-3
11. Sanda M, Restifo N, Walsh J, et al.: Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 1995, 87:280–285. DOI: 10.1093/jnci/87.4.280
12. Blades RA, Keating PJ, McWilliam LJ, et al.: Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 1995, 46:681–686. DOI: 10.1016/S0090-4295(99)80301-X
13. Simons JW, Mikhak B, Chang JF, et al.: Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999, 59:5160–5168. This study reports the first gene therapy clinical trial of an autologous vaccine for micrometastatic prostate cancer.
14. Simons J, Mikhak B, Chang J, et al.: Clinical activity and broken immunologic tolerance from ex vivo GM-CSF gene transduced prostate cancer vaccines. AUA 94th Annual Meeting; Dallas, Texas; 1999:51.
15. Chen AP, Bastian A, Dahut W, et al.: A phase I study of recombinant vaccinia virus that expresses prostate specific antigen (PSA) in adult patients with adenocarcinoma of the prostate. Proc Am Soc Clin Oncol, Los Angeles, CA; 1998:314a.
16. Eder JP, Kantoff PW, Roper K, et al.: A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 2000, 6:1632–1638.
17. Sanda MG, Smith DC, Charles LG, et al.: Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology 1999, 53:260–266. DOI: 10.1016/S0090-4295(98)00539-1
18. Naitoh J, Kaboo R, Tso C, et al.: Immunologic effects of interleukin-2 (IL-2) gene therapy in prostate cancer (CAP). AUA 94th Annual Meeting, San Diego, CA; 1998:12.
19. Pantuck AJ, Zisman A, Belldegrun AS: Gene therapy for prostate cancer at the University of California, Los Angeles: preliminary results and future directions. World J Urol 2000, 18:143–147. DOI: 10.1007/s003450050187
20. Patel B, Naitoh J, Stiles A, et al.: Effect of interleukin-2 (IL-2) gene therapy on prostate specific antigen in patients undergoing neoadjuvant or adjuvant gene therapy for prostate cancer. AUA 94th Annual Meeting, Dallas, TX; 1999:337.
21. Sanford MA, Hassen W, Atkinson G, et al.: Interleukin-12 gene therapy induced cell death through induction of FAS/FAS ligand-mediated death in metastatic mouse prostate cancer. AUA 94th Annual Meeting, Dallas, Texas; 1999:57.
22. Hyer M, Rubinchik S, Dong J-Y, et al.: Gene therapy of prostate cancer with adenovirus-mediated fas ligand (FasL) expression. AACR 90th Annual Meeting, Philadelphia, PA; 1999:173.
23. Heiser A, Dahm P, Yancey DR, et al.: Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol 2000, 164:5508–5514.
24. Small EJ, Fratesi P, Reese DM, et al.: Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000, 18:3894–3903.
25. Gotoh A, Kao C, Ko SC, et al.: Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21 WAF1/ CIP1 and p16CDKN4) in human prostate cancers. J Urol 1997, 158:636–641. DOI: 10.1016/S0022-5347(01)64574-9
26. Ko S-C, Gotoh A, Thalmann GN, et al.: Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model. Hum Gene Ther 1996, 7:1683–1691.
27. Eastham JA, Hall SJ, Sehgal I, et al.: In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 1995, 55:5151–5155.
28. Steiner MS, Lerner J, Greenberger M, et al.: Clinical phase I gene therapy trial using BRCA1 retrovirus is safe. J Urol 1998, 159:133. DOI: 10.1097/00005392-199805000-00110
29. Allay JA, Steiner MS, Zhang Y, et al.: Adenovirus p16 gene therapy for prostate cancer. World J Urol 2000, 18:111–120. DOI: 10.1007/s003450050182
30. Hsieh JT, Luo W, Song W, et al.: Tumor suppressive role of an androgen-regulated epithelial cell adhesion molecule (C-CAM) in prostate carcinoma cell revealed by sense and antisense approaches. Cancer Res 1995, 55:190–197.
31. Steiner MS, Anthony CT, Lu Y, et al.: Antisense c-myc retroviral vector suppresses established human prostate cancer. Hum Gene Ther 1998, 9:747–755.
32. Kim M, Wright M, Deshane J, et al.: A novel gene therapy strategy for elimination of prostate carcinoma cells from human bone marrow. Hum Gene Ther 1997, 8:157–170.
33. Logothetis CJ, Hossan E, Pettaway CA, et al.: AD-p53 intraprostatic gene therapy preceding radical prostatectomy (RP): an in vivo model for targeted therapy development. AUA 94th Annual Meeting, Dallas, Texas; 1999:297.
34. Hall SJ, Mutchnik SE, Chen SH, et al.: Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. Int J Cancer 1997, 70:183–187. DOI: 10.1002/(SICI)1097-0215(19970117)70:2<183::AID-IJC8>3.0.CO;2-T
35. Eastham JA, Chen SH, Sehgal I, et al.: Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther 1996, 7:515–523.
36. Hall SJ, Sanford MA, Atkinson G, et al.: Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer. Cancer Res 1998, 58:3221–3225.
37. Herman JR, Adler HL, Aguilar-Cordova E, et al.: In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther 1999, 10:1239–1249. This study reports the first phase I clinical study of direct HSV-tk prostate injection for radio-recurrent prostate carcinoma and has served as the basis for several current trials. DOI: 10.1089/10430349950018229
38. Shalev M, Kadmon D, Teh BS, et al.: Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J Urol 2000, 163:1747–1750. DOI: 10.1016/S0022-5347(05)67534-9
39. Ayala G, Wheeler TM, Shalev M, et al.: Cytopathic effect of in situ gene therapy in prostate cancer. Hum Pathol 2000, 31:866–870. This report demonstrates the first correlative histology for neoadjuvant gene therapy prior to radical prostatectomy. DOI: 10.1053/hupa.2000.8453
40. Koeneman KS, Kao C, Ko SC, et al.: Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J Urol 2000, 18:102–110. DOI: 10.1007/s003450050181
41. Blackburn RV, Galoforo SS, Corry PM, et al.: Adenoviral-mediated transfer of a heat-inducible double suicide gene into prostate carcinoma cells. Cancer Res 1998, 58:1358–1362.
42. Kim SJ, Gardner TA, Ko S-C, et al.: Enhancement of bystander prostate cancer cell killing by the utilization of genetically engineered bone stromal cells that confer either cytosine deaminase or thymidine kinase gene. J Urol 1999, 58.
43. Martiniello-Wilks R, Garcia-Aragon J, Daja MM, et al.: In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. Hum Gene Ther 1998, 9:1617–1626.
44. Segawa T, Takebayashi H, Kakehi Y, et al.: Prostate-specific amplification of expanded polyglutamine expression: a novel approach for cancer gene therapy. Cancer Res 1998, 58:2282–2287.
45. Marcelli M, Cunningham GR, Walkup M, et al.: Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: overexpression of caspase-7 as a new gene therapy strategy for prostate cancer. Cancer Res 1999, 59:382–390.
46. Dorai T, Perlman H, Walsh K, et al.: Enhanced apoptosis of prostate cancer cells by adenoviral hammerhead ribozyme mediated disruption of bcl-2. AACR 90th Annual Meeting, Philadelphia, PA; 1999:482.
47. Bischoff JR, Kirn DH, Williams A, et al.: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996, 274:373–376. DOI: 10.1126/science.274.5286.373
48. Brooks JD, Bova GS, Ewing CM, et al.: An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res 1996, 56:3814–3822.
49. Rodriguez R, Schuur ER, Lim HY, et al.: Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997, 57:2559–2563.
50. Yu DC, Sakamoto GT, Henderson DR: Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res 1999, 59:1498–1504.
51. Simons J, Baccala A, Lim H. Ex vivo and in vivo gene therapy strategies for prostate cancer: emerging clinical pharmacology. In Gene Therapy of Cancer. Edited by Lattime E, Gerson S. San Diego: Academic Press; 1999:333–345.
52. Hall SJ, Mutchnik SE, Yang G, et al.: Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer. Cancer Gene Ther 1999, 6:54–63. DOI: 10.1038/sj.cgt.7700004
53. Nielsen LL, Lipari P, Dell J, et al.: Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin Cancer Res 1998, 4:835–846.
54. Yin L, Fu S, Peng X, et al.: Cytosine deaminase (CDA) adenoviral vector (ADV) and administration of the non toxic prodrug 5-fluorocytosine (5FC) used for therapy sensitization (TS) of prostate cancer cells. Paper presented at Annual Meeting of American Society of Clinical Oncology. May 15–19, 1998. Los Angeles, CA.
55. Atkinson G, Hall SJ: Prodrug activation gene therapy a nd external beam irradiation in the treatment of prostate cancer. Urology 1999, 54:1098–1104. DOI: 10.1016/S0090-4295(99)00295-2
56. Anello R, Cohen S, Atkinson G, et al.: Adenovirus mediated cytosine deaminase gene transduction and 5-FLUOROCYTOSINE therapy sensitizes mouse prostate cancer cells to irradiation. J Urol 2000, 164:2173–2177. DOI: 10.1016/S0022-5347(05)66992-3
57. Hassen W, Sanford M, Atkinson G, et al.: Natural killer cells induced by herpes simplex virus thymidine kinase gene transduction and ganciclovir therapy are enhanced by interleukin-12 gene therapy in an othotopic model of mouse prostate cancer. AUA 95th Annual Meeting, Dallas, Texas; 1999:53.
58. Rogulski KR, Wing MS, Paielli DL, et al.: Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum Gene Ther 2000, 11:67–76. DOI: 10.1089/10430340050016166